DENVER, CO,
Feb. 3 /PRNewswire-FirstCall/ -
Medical International Technology Inc. (MDLH.OB)
www.mitneedlefree.com is pleased to announce its progress in
China.
Based on the results obtained in two separate
pivotal clinical trials over the past six months, the Chinese SFDA
authorities have approved and issued to our Joint Venture
Corporation the official licence to sell MED-JET®
products.
"We are extremely delighted to have received the
official certification to sell MED-JET® products to the
largest human medical market in the world," said MIT President and CEO, Mr Karim Menassa. "We can now execute our business
plan, which forecasts multi million dollars of sales in different
niche markets as well as hospitals and clinics across all Chinese
provinces.
MIT China General Manager Mr. Ethan Sun said "The official SFDA Certification
has been obtained thanks to great collaboration between MIT China
employees and hospital personnel."
Dr. Francis
Bellido, Vice-President and Chief Strategy Officer of
MIT Canada believes that access to the
Chinese market, with its growing middle class population demanding
more quality healthcare, could be instrumental for MIT due to the huge volume of needle-free injectors
needed to satisfy the staggering Chinese demand"
Medical International Technology Inc. is proud
to continue providing a safe and effective means to help prevent
the spread of deadly diseases to both humans and animals through
the use of the Med-Jet® and Agro-Jet®
needle-free injection system.
About Medical International Technology, Inc. MIT
CANADA, with offices in
Montreal, is a subsidiary of
Denver, Colorado-based Medical
International Technology, Inc. (MIT USA), which specializes in the
development, production, marketing and sale of needle-free
injectors both for humans and animals, for individual and mass
vaccinations.
The statements which are not historical facts
contained in this press release are forward-looking statements that
involve certain risks and uncertainties, including but not limited
to risks associated with the uncertainty of future financial
results, additional financing requirements, development and
acquisition of new product lines and services, government approval
processes, the impact of competitive products or pricing a
technological changes, the effect of economic conditions and other
uncertainties, and the risk factors set forth from time to time in
the Company's SEC reports, including but not limited to its annual
report on Form 10-KSB; its quarterly reports on Forms 10-QSB; and
any reports on Form 8-K. Medical International Technology Inc.
takes no obligation to update or correct forward-looking
statements.
SOURCE MEDICAL INTERNATIONAL TECHNOLOGIES INC.
Copyright b. 3 PR Newswire